CEO defends raising price of drug from $13.50 a pill to $750: 'We have to turn a profit'
A former hedge fund manager is justifying his startup company's decision to increase the price of a life-saving drug from $13.50 per pill to $750 by saying it's necessary in order to create better medicine in the future.
Martin Shkreli's Turing Pharmaceuticals acquired the drug Daraprim in August, The Guardian reports. Daraprim is used to treat toxoplasmosis, a parasitic infection that can be fatal when it affects babies born to infected mothers and people with compromised immune systems due to AIDS and certain cancers. Shkreli told Bloomberg News on Monday the company needs to "turn a profit on the drug," since research is costly and they want to come up with a newer version. Daraprim is the trade name for the generic drug pyrimethamine, which was developed in the 1940s and is on the World Health Organization's List of Essential Medicines.
The HIV Medicine Association and the Infectious Diseases Society of America sent a letter to Turing Pharmaceuticals earlier in September, and said the 50-fold increase in price was "unjustifiable for the medically-vulnerable patient population" and "unsustainable for the health care system." Shkreli said Monday Daraprim is actually underpriced, and declared: "If you cannot afford the drug we will give it away for free."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia is night editor for TheWeek.com. Her writing and reporting has appeared in Entertainment Weekly and EW.com, The New York Times, The Book of Jezebel, and other publications. A Southern California native, Catherine is a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
'Horror stories of women having to carry nonviable fetuses'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
Haiti interim council, prime minister sworn in
Speed Read Prime Minister Ariel Henry resigns amid surging gang violence
By Peter Weber, The Week US Published
-
Today's political cartoons - April 26, 2024
Cartoons Friday's cartoons - teleprompter troubles, presidential immunity, and more
By The Week US Published
-
Puffed rice and yoga: inside the collapsed tunnel where Indian workers await rescue
Speed Read Workers trapped in collapsed tunnel are suffering from dysentery and anxiety over their rescue
By Sorcha Bradley, The Week UK Published
-
More than 2,000 dead following massive earthquake in Morocco
Speed Read
By Justin Klawans Published
-
Mexico's next president will almost certainly be its 1st female president
Speed Read
By Peter Weber Published
-
North Korea's Kim to visit Putin in eastern Russia to discuss arms sales for Ukraine war, U.S. says
Speed Read
By Peter Weber Published
-
Gabon's military leader sworn in following coup in latest African uprising
Speed Read
By Justin Klawans Published
-
Nobody seems surprised Wagner's Prigozhin died under suspicious circumstances
Speed Read
By Peter Weber Published
-
Western mountain climbers allegedly left Pakistani porter to die on K2
Speed Read
By Justin Klawans Published
-
'Circular saw blades' divide controversial Rio Grande buoys installed by Texas governor
Speed Read
By Peter Weber Published